ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,521 to 3,540 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Care Transitions Intervention vs Usual Care: deaths from any cause2 of 987

5 of 992

-0.3 points

-1.0 to 0.3

1,979NCT02520661

Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health

Care Transitions Intervention vs Usual Care: serious adverse events51 of 987

51 of 992

0.0 points

-1.9 to 2.0

1,979NCT02520661

Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health

Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths12 of 987

9 of 989

0.3 points

-0.7 to 1.3

1,976NCT00359801

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

Exubera® vs Non-Exubera®: serious adverse events124 of 987

109 of 989

1.5 points

-1.3 to 4.4

1,976NCT00359801

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 36 (End of Study) Post Enrollment53 of 981

58 of 995

-0.4 points

-2.5 to 1.6

1,976NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With HIV-1 Infection Diagnosed From Month 13 Through Month 24 Post Enrollment32 of 981

35 of 995

-0.3 points

-1.9 to 1.4

1,976NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Evolocumab vs Placebo: serious adverse events212 of 983

204 of 990

1.0 points

-2.6 to 4.6

1,973NCT02207634

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Tobacco Quitline Only vs Tobacco Quitline Plus Smoke Free Homes: deaths from any cause1 of 987

0 of 986

0.1 points

-0.3 to 0.6

1,973NCT04311983

Interventions to Help More Low-income Smokers Quit

Pinard vs Doppler: Identification of Abnormal Fetal Heart Rate46 of 979

75 of 992

-2.9 points

-5.0 to -0.7

1,971NCT02273037

Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda

Pinard Horn vs Fetal Heart Rate Doppler: Stillbirth and Neonatal Death6 of 979

11 of 992

-0.5 points

-1.4 to 0.4

1,971NCT02273037

Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda

Pinard vs Doppler: deaths from any cause6 of 979

11 of 992

-0.5 points

-1.4 to 0.4

1,971NCT02273037

Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda

This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 30-day Point Prevalence Abstinence (Responder Only)314 of 976

239 of 995

8.2 points

4.2 to 12.1

1,971NCT04251273

Text Message Quit Vaping Intervention for Young Adults

Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events181 of 995

182 of 974

-0.5 points

-3.9 to 2.9

1,969NCT00009737

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 7-day Point Prevalence Abstinence (Responder Only)440 of 973

385 of 994

6.5 points

2.1 to 10.8

1,967NCT04251273

Text Message Quit Vaping Intervention for Young Adults

Cardiovascular Death vs Myocardial Re-infarction: Participants With Cardiac Events During Follow-up.92 of 982

51 of 982

4.2 points

1.9 to 6.5

1,964NCT01377402

ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study

Liraglutide 1.8 mg vs Oral Antidiabetic Drug: deaths from any cause1 of 980

8 of 984

-0.7 points

-1.5 to -0.1

1,964NCT02730377

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Liraglutide 1.8 mg vs Oral Antidiabetic Drug: serious adverse events92 of 980

81 of 984

1.2 points

-1.4 to 3.7

1,964NCT02730377

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

VITALITY 2 vs Medtronic Family: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge Visit246 of 985

187 of 977

5.8 points

2.2 to 9.5

1,962NCT00148954

RIGHT: Rhythm ID Going Head-to-Head Trial

Sema 2.4 mg vs Placebo: deaths from any cause1 of 1,306

1 of 655

-0.1 points

-0.8 to 0.3

1,961NCT03548935

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Sema 2.4 mg vs Placebo: serious adverse events128 of 1,306

42 of 655

3.4 points

0.8 to 5.8

1,961NCT03548935

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=177"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=177

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02520661-deaths",
        "title": "Care Transitions Intervention vs Usual Care: deaths from any cause",
        "summary": "2 of 987 against 5 of 992; risk difference -0.3 points, 95% interval -1.0 to 0.3; NCT02520661, Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health",
        "record": "/library/comparisons/NCT02520661-deaths",
        "nct_id": "NCT02520661",
        "kind": "deaths",
        "participants": 1979,
        "risk_difference": {
          "value": -0.0030139801287707942,
          "lower": -0.009877498629933342,
          "upper": 0.003048493807087101
        },
        "group_1": "2 of 987",
        "group_2": "5 of 992",
        "difference": "-0.3 points",
        "interval": "-1.0 to 0.3",
        "trial_title": "Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health"
      },
      {
        "id": "NCT02520661-sae",
        "title": "Care Transitions Intervention vs Usual Care: serious adverse events",
        "summary": "51 of 987 against 51 of 992; risk difference 0.0 points, 95% interval -1.9 to 2.0; NCT02520661, Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health",
        "record": "/library/comparisons/NCT02520661-sae",
        "nct_id": "NCT02520661",
        "kind": "serious-adverse-events",
        "participants": 1979,
        "risk_difference": {
          "value": 0.00026044220021570474,
          "lower": -0.019479948587876866,
          "upper": 0.020023591847744125
        },
        "group_1": "51 of 987",
        "group_2": "51 of 992",
        "difference": "0.0 points",
        "interval": "-1.9 to 2.0",
        "trial_title": "Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=178",
  "request_id": "mcUlTILEbEVCPra7"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?